Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15698958 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL14709158 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL28489991 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL12280418 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL2362689 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL15859653 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL1834044 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL14709006 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL1255498 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL12910763 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2707363-B1 | A PROCESS FOR THE PREPARATION OF BENZYL [(3AS,4R,6S,6AR)-6-HYDROXY-2,2- DIMETHYLTETRAHYDRO-3AH-CYCLOPENTA[D][1,3]DIOXOL]-4-YL]CARBAMATE AND INTERMEDIATES IN THE PROCESS | ASTRAZENECA AB (SE) | 2015-10-21 | — | — | EP | claimed |
| US-9079873-B2 | Process for the preparation of benzyl [(3aS,4R,6S,6aR)-6-hydroxy-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol]-4-yl]carbamate and intermediates in the process | ASTRAZENECA AB (SE) | 2015-07-14 | — | — | US | claimed |
| WO-2012063126-A2 | IMPROVED PROCESSES FOR PREPARING PURE (3AR,4S,6R,6AS)-6-AMINO-2,2-DIMETHYLTETRAHDRO-3AH-CYCLOPENTA[D] [1,3]-DIOXOL-4-OL AND ITS KEY STARTING MATERIAL | ACTAVIS GROUP PTC EHF (IS) | 2012-05-18 | — | — | WO | claimed |
| US-12318388-B2 | Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling | Université de Liège (BE) | 2025-06-03 | — | — | US | disclosed |
| CN-113329753-B | Pyrimidine derivatives for the prevention and treatment of gram-negative bacterial infections, pollution and fouling | 列日大学 | 2024-08-13 | — | — | CN | disclosed |
| EP-3955929-B1 | NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | UNIV LIEGE (BE) | 2024-05-15 | — | — | EP | disclosed |
| CN-111386271-B | Pyrimidine derivatives for the prevention and treatment of bacterial infections | 列日大学 | 2023-05-30 | — | — | CN | disclosed |
| US-20230062975-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | SPRING MILL PHARMA, INC. | 2023-03-02 | — | — | US | disclosed |
| CN-109890797-B | Substituted carbon nucleoside derivatives useful as anticancer agents | 辉瑞公司 | 2023-02-28 | — | — | CN | disclosed |
| US-11566001-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-3752506-B1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | UNIV LIEGE (BE) | 2022-12-14 | — | — | EP | disclosed |
| WO-2009064249-A1 | A PROCESS FOR THE PREPARATION OF (3AR,4S, 6R, 6AS)-6-AMINO-2, 2- DIMETHYLTETRAHYDRO-3AH-CYCLOPENTA[D] [1,3] DIOXOL-4-OL DIBENZOYL-L-TARTRATE AND TO PRODUCTS OF SAID PROCESS | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| US-20070293513-A1 | Cristalline and amorphous form of a triazolo (4,5-d) pyridimine compound | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| US-7265124-B2 | Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound | ASTRAZENECA AB (SE) | 2007-09-04 | — | — | US | disclosed |
| US-20070173518-A1 | CRISTALLINE AND AMORPHOUS FORM OF A TRIAZOLO (4,5-D) PYRIDIMINE COMPOUND | ASTRAZENECA AB (SE) | 2007-07-26 | — | — | US | disclosed |
| EP-1289992-B1 | NEW CRYSTALLINE FORM OF A TRIAZOLO(4,5-D)PYRIMIDINE COMPOUND | ASTRAZENECA AB (SE) | 2006-03-15 | — | — | EP | disclosed |
| US-6974868-B2 | Compounds | ASTRAZENECA AB (SE) | 2005-12-13 | — | — | US | disclosed |
| EP-1493745-A1 | New crystalline and amorphous form of a triazolo(4,5-D)pyrimidine compound | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| US-20030181469-A1 | Crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound | ASTRA ZENCA AB (SE) | 2003-09-25 | — | — | US | disclosed |
| US-20030144305-A1 | Novel compounds | ASTRAZENECA AB | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293513-A1 | Cristalline and amorphous form of a triazolo (4,5-d) pyridimine compound | PNPO, MT-ND5, CYP3A5 | MGAM 3644/4885CA1 2843/4885CA2 2163/4885 |
| US-20230062975-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | MGAM 4436/4885CA1 4284/4885CA2 4777/4885 |
| US-11566001-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | MGAM 4436/4885CA1 4284/4885CA2 4777/4885 |
| US-12318388-B2 | Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling | PIGS, TYMP, TYMS | MGAM 629/4885CA1 4266/4885CA2 3816/4885 |
| US-20030181469-A1 | Crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound | TYMP, TYMS, DPYD | MGAM 3878/4885CA1 2837/4885CA2 1671/4885 |
| US-20030144305-A1 | Novel compounds | DPYD, TYMP, NUDT15 | MGAM 4083/4885CA1 4780/4885CA2 3739/4885 |
| US-20070173518-A1 | CRISTALLINE AND AMORPHOUS FORM OF A TRIAZOLO (4,5-D) PYRIDIMINE COMPOUND | MT-ND5, PNPO, PDXK | MGAM 3783/4885CA1 3113/4885CA2 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.